Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Clinical features and structured clinical evaluation of vasculitis.

Ponte C, Águeda AF, Luqmani RA.

Best Pract Res Clin Rheumatol. 2018 Feb;32(1):31-51. doi: 10.1016/j.berh.2018.10.001. Epub 2018 Nov 22. Review.

PMID:
30526897
2.

Defining disease activity and damage in patients with small-vessel vasculitis.

Merkel PA.

Cleve Clin J Med. 2012 Nov;79 Suppl 3:S11-5. doi: 10.3949/ccjm.79.s3.03.

PMID:
23203638
3.

Measuring vasculitis with numbers: outcome scores.

Batu ED, Ozen S.

Curr Rheumatol Rev. 2019 Nov 25. doi: 10.2174/1573397115666191126093927. [Epub ahead of print]

PMID:
31804163
4.

The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis.

Merkel PA, Aydin SZ, Boers M, Direskeneli H, Herlyn K, Seo P, Suppiah R, Tomasson G, Luqmani RA.

J Rheumatol. 2011 Jul;38(7):1480-6. doi: 10.3899/jrheum.110276.

5.

Brief Report: Childhood-Onset Systemic Necrotizing Vasculitides: Long-Term Data From the French Vasculitis Study Group Registry.

Iudici M, Puéchal X, Pagnoux C, Quartier P, Agard C, Aouba A, Büchler M, Cevallos R, Cohen P, de Moreuil C, Guilpain P, Le Quellec A, Roblot P, Serratrice J, Bachmeyer C, Daugas É, Terrier B, Mouthon L, Guillevin L; French Vasculitis Study Group.

Arthritis Rheumatol. 2015 Jul;67(7):1959-65. doi: 10.1002/art.39122.

6.

Prognosis and future developments in vasculitis.

Basu N, Karabayas M, Pusey C.

Best Pract Res Clin Rheumatol. 2018 Feb;32(1):148-165. doi: 10.1016/j.berh.2018.08.011. Epub 2018 Sep 22. Review.

7.

Systemic vasculitides: a critical digest of the most recent literature.

Stagnaro C, Cioffi E, Talarico R, Della Rossa A.

Clin Exp Rheumatol. 2015 Mar-Apr;33(2 Suppl 89):S-145-54. Epub 2015 May 26. Review.

PMID:
26016767
8.

Patient-reported outcomes in ANCA-associated vasculitis. A comparison between Birmingham Vasculitis Activity Score and routine assessment of patient index data 3.

Annapureddy N, Elsallabi O, Baker J, Sreih AG.

Clin Rheumatol. 2016 Feb;35(2):395-400. doi: 10.1007/s10067-015-2921-2. Epub 2015 Mar 31.

PMID:
25822996
9.

Anti-neutrophil cytoplasmic antibody-associated vasculitis, large vessel vasculitis and Kawasaki disease in Japan.

Kobayashi S, Fujimoto S, Takahashi K, Suzuki K.

Kidney Blood Press Res. 2010;33(6):442-55. doi: 10.1159/000320383. Epub 2010 Nov 10. Review.

10.

[ANCA-associated vasculitis].

Holle JU.

Internist (Berl). 2015 Jan;56(1):41-50; quiz 51-2. doi: 10.1007/s00108-014-3613-8. German.

PMID:
25502657
11.

Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Using the OMERACT Process.

Robson JC, Milman N, Tomasson G, Dawson J, Cronholm PF, Kellom K, Shea J, Ashdown S, Boers M, Boonen A, Casey GC, Farrar JT, Gebhart D, Krischer J, Lanier G, McAlear CA, Peck J, Sreih AG, Tugwell PS, Luqmani RA, Merkel PA.

J Rheumatol. 2015 Nov;42(11):2204-9. doi: 10.3899/jrheum.141143. Epub 2015 Sep 1. Review.

12.

Patient and physician perspectives on the impact of health-related quality of life in Mexican patients with ANCA-associated vasculitis.

Hinojosa-Azaola A, Jiménez-González A, Alcocer-Castillejos N.

Rheumatol Int. 2018 Apr;38(4):631-640. doi: 10.1007/s00296-017-3904-1. Epub 2017 Dec 15.

PMID:
29247347
13.

Current status of outcome measure development in vasculitis.

Merkel PA, Aydin SZ, Boers M, Cornell C, Direskeneli H, Gebhart D, Hatemi G, Luqmani R, Matteson EL, Milman N, Robson J, Seo P, Tomasson G.

J Rheumatol. 2014 Mar;41(3):593-8. doi: 10.3899/jrheum.131248. Epub 2014 Jan 15.

14.

Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016.

Sreih AG, Alibaz-Oner F, Kermani TA, Aydin SZ, Cronholm PF, Davis T, Easley E, Gul A, Mahr A, McAlear CA, Milman N, Robson JC, Tomasson G, Direskeneli H, Merkel PA.

J Rheumatol. 2017 Dec;44(12):1933-1937. doi: 10.3899/jrheum.161467. Epub 2017 Sep 1.

15.

OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis.

Robson JC, Tomasson G, Milman N, Ashdown S, Boonen A, Casey GC, Cronholm PF, Cuthbertson D, Dawson J, Direskeneli H, Easley E, Kermani TA, Farrar JT, Gebhart D, Lanier G, Luqmani RA, Mahr A, McAlear CA, Peck J, Shea B, Shea JA, Sreih AG, Tugwell PS, Merkel PA.

J Rheumatol. 2017 Oct;44(10):1529-1535. doi: 10.3899/jrheum.161139. Epub 2017 Sep 1.

16.

Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.

Lenert A, Lenert P.

Drug Des Devel Ther. 2015 Jan 7;9:333-47. doi: 10.2147/DDDT.S67264. eCollection 2015. Review.

17.

[Large vessel involvement in ANCA-associated vasculitis: Report of one case].

Vega J, Guarda FJ.

Rev Med Chil. 2015 Sep;143(9):1206-9. doi: 10.4067/S0034-98872015000900015. Spanish.

18.

Ocular manifestations of systemic disease: antineutrophil cytoplasmic antibody-associated vasculitis.

Schmidt J, Pulido JS, Matteson EL.

Curr Opin Ophthalmol. 2011 Nov;22(6):489-95. doi: 10.1097/ICU.0b013e32834bdfe2. Review.

PMID:
21918443
19.

State of the art in the treatment of systemic vasculitides.

Luqmani RA.

Front Immunol. 2014 Oct 13;5:471. doi: 10.3389/fimmu.2014.00471. eCollection 2014. Review.

20.

Biological drugs in ANCA-associated vasculitis.

Lutalo PM, D'Cruz DP.

Int Immunopharmacol. 2015 Aug;27(2):209-12. doi: 10.1016/j.intimp.2015.04.023. Epub 2015 Apr 20. Review.

PMID:
25907243

Supplemental Content

Support Center